|
- Edwards Lifesciences - the leader in heart valves hemodynamic . . .
Transcatheter mitral and tricuspid technologies Critical care technologies* Surgical valve technologies *Edwards Lifesciences Critical Care is now part of BD (Becton, Dickinson and Company)
- Edwards Lifesciences Corp - Overview
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to
- Newsroom - Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to
- Our leaders | Edwards Lifesciences
Building from Edwards’ foundation rooted in the company’s Credo, the patient-focused culture and the unique innovation strategy, Zovighian and the global Edwards employees are united and inspired to enable the company’s sustainable growth and extend its global leadership
- Contact Us | Edwards Lifesciences
5:00am - 4:30pm PST,M-F 800 424 3278 We usually respond within one business day customerservice_us@edwards com
- Press Releases | Edwards Lifesciences
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION Read more
- Global Locations | Edwards Lifesciences
USA and Canada Main locations Global headquarters Edwards Lifesciences Corp One Edwards Way Irvine, CA 92614
- Edwards Lifesciences Completes Sale of Critical Care
IRVINE, Calif -- (BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX) for $4 2 billion in an all-cash transaction
|
|
|